Standout Papers

Comparison of the efficacy and safety of n... 1997 2026 2006 2016 3.2k
  1. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials (2013)
    Christian T. Ruff, Robert P. Giugliano et al. The Lancet
  2. Oral Apixaban for the Treatment of Acute Venous Thromboembolism (2013)
    Giancarlo Agnelli, Harry R. Büller et al. New England Journal of Medicine
  3. Low-Molecular-Weight Heparins (1997)
    Jeffrey I. Weitz New England Journal of Medicine
  4. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism (2017)
    Gary E. Raskob, Nick van Es et al. New England Journal of Medicine
  5. Idarucizumab for Dabigatran Reversal (2015)
    Charles V. Pollack, Paul A. Reilly et al. New England Journal of Medicine
  6. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. (1990)
    Jeffrey I. Weitz, Monika Hudoba et al. Journal of Clinical Investigation
  7. Apixaban for Extended Treatment of Venous Thromboembolism (2012)
    Giancarlo Agnelli, Harry R. Büller et al. New England Journal of Medicine
  8. A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis (1996)
    Mark Levine, Michael Gent et al. New England Journal of Medicine
  9. Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events (2002)
    John W. Eikelboom, Jack Hirsh et al. Circulation
  10. Parenteral Anticoagulants (2012)
    David García, Trevor Baglin et al. CHEST Journal
  11. Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review (1996)
    Jeffrey I. Weitz, John Byrne et al. Circulation
  12. Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism (2003)
    Clive Kearon, Jeffrey S. Ginsberg et al. New England Journal of Medicine
  13. Parenteral Anticoagulants (2008)
    Jack Hirsh, Kenneth A. Bauer et al. CHEST Journal
  14. Accuracy of clinical assessment of deep-vein thrombosis (1995)
    P.S. Wells, Jack Hirsh et al. The Lancet
  15. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (2017)
    Jeffrey I. Weitz, Anthonie W.A. Lensing et al. New England Journal of Medicine
  16. Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis (2014)
    Harry R. Büller, Claudette Bethune et al. New England Journal of Medicine
  17. Medical device‐induced thrombosis: what causes it and how can we prevent it? (2015)
    Iqbal Jaffer, James C. Fredenburgh et al. Journal of Thrombosis and Haemostasis
  18. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients (2011)
    Samuel Z. Goldhaber, Alain Leizorovicz et al. New England Journal of Medicine
  19. The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies (2014)
    Susan R. Kahn, Anthony J. Comerota et al. Circulation
  20. A Test in Context: D-Dimer (2017)
    Jeffrey I. Weitz, James C. Fredenburgh et al. Journal of the American College of Cardiology
  21. Thrombosis: a major contributor to the global disease burden (2014)
    Gary E. Raskob, Pantep Angchaisuksiri et al. Journal of Thrombosis and Haemostasis
  22. Prosthetic Heart Valve Thrombosis (2016)
    George Dangas, Jeffrey I. Weitz et al. Journal of the American College of Cardiology
  23. Therapeutic strategies for thrombosis: new targets and approaches (2020)
    Nigel Mackman, Wolfgang Bergmeier et al. Nature Reviews Drug Discovery
  24. Abelacimab for Prevention of Venous Thromboembolism (2021)
    Peter Verhamme, B. Alexander Yi et al. New England Journal of Medicine
  25. Milvexian for the Prevention of Venous Thromboembolism (2021)
    Jeffrey I. Weitz, John Strony et al. New England Journal of Medicine
  26. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation (2025)
    Christian T. Ruff, Siddharth M. Patel et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 87 standout
Sub-graph 1 of 19

Citing Papers

Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture
2023 Standout
Zwitterionic Biomaterials
2022 Standout
12 intermediate papers

Works of Jeffrey I. Weitz being referenced

Single and multi-functional coating strategies for enhancing the biocompatibility and tissue integration of blood-contacting medical implants
2020
Medical device‐induced thrombosis: what causes it and how can we prevent it?
2015 Standout
and 10 more

Author Peers

Author Last Decade Papers Cites
Jeffrey I. Weitz 22831 20237 9016 517 40.1k
Harry R. Büller 19612 25437 8368 454 36.4k
Mark Crowther 19077 20658 9022 573 38.6k
Martin H. Prins 17339 19486 6708 381 33.8k
Jack Hirsh 22531 22053 8190 345 37.9k
Sam Schulman 21025 20968 7556 494 33.5k
John A. Heit 14795 22992 6328 214 30.0k
Michael Gent 20314 16802 5160 229 35.3k
Mark N. Levine 8778 12063 3792 317 30.6k
Marcel Levi 6433 7528 9703 523 37.9k
Hugo Ten Cate 5485 5342 7593 567 21.1k

All Works

Loading papers...

Rankless by CCL
2026